Clinical pharmacokinetics of dorzolamide (Q34522133)

2 August 2017

1 reference

title

Clinical pharmacokinetics of dorzolamide (English)

1 reference

2 August 2017

1 reference

Jens Martens-Lobenhoffer

series ordinal

1

1 reference

2 August 2017

Peter Banditt

series ordinal

2

1 reference

2 August 2017

publication date

1 January 2002

1 reference

Clinical Pharmacokinetics

2 August 2017

published in

1 reference

2 August 2017

volume

41

1 reference

2 August 2017

issue

3

1 reference

2 August 2017

page(s)

197-205

1 reference

Failure of acetazolamide to decrease intraocular pressure in patients with carbonic anhydrase II deficiency.

2 August 2017

cites work

1 reference

12 December 2020

Influence of pH on the kinetics of complex formation between aromatic sulfonamides and human carbonic anhydrase

1 reference

12 December 2020

Review of glaucoma research

1 reference

12 December 2020

Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor

1 reference

12 December 2020

The development of topical carbonic anhydrase inhibitors

1 reference

12 December 2020

Topical ocular drug delivery: recent developments and future challenges

1 reference

12 December 2020

Whole-blood pharmacokinetics and metabolic effects of the topical carbonic anhydrase inhibitor dorzolamide

1 reference

12 December 2020

Low level determination of dorzolamide and its de-ethylated metabolite in human plasma by liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry

1 reference

12 December 2020

Carbonic anhydrase inhibitors: inhibition of isozymes I, II and IV with N-hydroxysulfonamides--a novel class of intraocular pressure lowering agents

1 reference

12 December 2020

Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors

1 reference

12 December 2020

A six-week dose-response study of the ocular hypotensive effect of dorzolamide with a one-year extension. Dorzolamide Dose-Response Study Group.

1 reference

12 December 2020

Nonlinear dorzolamide pharmacokinetics in rats: concentration-dependent erythrocyte distribution and drug-metabolite displacement interaction

1 reference

12 December 2020

A comparison of L-671,152 and MK-927, two topically effective ocular hypotensive carbonic anhydrase inhibitors, in experimental animals

1 reference

12 December 2020

Dorzolamide, a 40-year wait. From an oral to a topical carbonic anhydrase inhibitor for the treatment of glaucoma.

1 reference

12 December 2020

Sulfonamides Do Not Reach the Retina in Therapeutic Amounts after Topical Application to the Cornea

1 reference

12 December 2020

Population pharmacokinetics of 2% topical dorzolamide in the aqueous humor of humans.

1 reference

12 December 2020

Pharmacological advances in the treatment of glaucoma

1 reference

12 December 2020

Determination of MK-507, a novel topically effective carbonic anhydrase inhibitor, and its de-ethylated metabolite in human whole blood, plasma, and urine by high-performance liquid chromatography

1 reference

12 December 2020

Carbonic anhydrase inhibitors. Part 71

1 reference

12 December 2020

Penetration into the anterior chamber via the conjunctival/scleral pathway

1 reference

12 December 2020

Non-invasive assessment of ocular pharmacokinetics using Confocal Raman Spectroscopy

1 reference

12 December 2020

Carbonic anhydrase: chemistry, physiology, and inhibition

1 reference

12 December 2020

Indirect chiral separation and analyses in human biological fluids of the stereoisomers of a thienothiopyran-2-sulfonamide (TRUSOPT), a novel carbonic anhydrase inhibitor with two chiral centers in the molecule

1 reference

12 December 2020

Dorzolamide: Development and clinical application of a topical carbonic anhydrase inhibitor

1 reference

12 December 2020

The effect of temperature on the binding of sulfonamides to carbonic anhydrase isoenzymes I, II, and IV

1 reference

12 December 2020

Development and pharmacological characterization of a modified procedure for the measurement of carbonic anhydrase activity

1 reference

12 December 2020

Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension

1 reference

12 December 2020

Trusopt, a topical carbonic anhydrase inhibitor.

1 reference

12 December 2020

Localization of carbonic anhydrase IV in a specific capillary bed of the human eye

1 reference

12 December 2020

The preclinical pharmacology of dorzolamide hydrochloride, a topical carbonic anhydrase inhibitor

1 reference

12 December 2020

Carbonic anhydrase inhibitors: inhibition of isozymes I, II and IV with heterocyclic mercaptans, sulfenamides, sulfonamides and their metal complexes

1 reference

12 December 2020

Binding of dorzolamide and its metabolite, N-deethylated dorzolamide, to human erythrocytes in vitro

1 reference

12 December 2020

Ocular absorption, blood levels, and excretion of dorzolamide, a topically active carbonic anhydrase inhibitor

1 reference

12 December 2020

New medical therapies for glaucoma

1 reference

12 December 2020

Carbonic Anhydrase Inhibitors. Synthesis of Water-Soluble, Topically Effective, Intraocular Pressure-Lowering Aromatic/Heterocyclic Sulfonamides Containing Cationic or Anionic Moieties: Is the Tail More Important than the Ring?1

1 reference

12 December 2020

In vitro metabolism of dorzolamide, a novel potent carbonic anhydrase inhibitor, in rat liver microsomes

1 reference

12 December 2020

The in vitro activity of sulfonamides against red cell carbonic anhydrases. Effect of ionic and substrate variation on the hydration reaction

1 reference

12 December 2020

10.2165/00003088-200241030-00004

Identifiers

DOI

1 reference

Dimensions Publication ID

2 August 2017

1016100627

0 references

1 reference